On March 30, 2020, China’s National Medical Products Administration (NMPA) published two long-awaited implementing rules under the most recent Drug Administration Law (DAL): the Drug Registration Regulation (DRR) and the Drug Manufacturing Regulation (DMR). They are effective July 1, 2020. Below are highlights most relevant to multinational pharmaceutical companies with operations in China.
Sidley Austin LLP provides this information as a service to clients and other friends for educational purposes only. It should not be construed or relied on as legal advice or to create a lawyer-client relationship.
Attorney Advertising - For purposes of compliance with New York State Bar rules, our headquarters are Sidley Austin LLP, 787 Seventh Avenue, New York, NY 10019, 212.839.5300; One South Dearborn, Chicago, IL 60603, 312.853.7000; and 1501 K Street, N.W., Washington, D.C. 20005, 202.736.8000.